TTX-381, a one-time, subretinal AAV gene therapy, is designed to deliver a functional TPP1 gene copy directly to retinal cells to produce the missing TPP1 enzyme and preserve patient vision. The post Andelyn and Tern Therapeutics Partner on Gene Therapy Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News.
